COGNITIVE ASSESSMENT WITH COGNIVUECLARITY®: PSYCHOMETRIC PROPERTIES AND ENHANCED NORMATIVE RANGES IN A DIVERSE POPULATION

Abstract

ABSTRACTBackgroundDetecting cognitive impairment in clinical practice is challenging as most instruments do not perform well in diverse samples of older adults. These same instruments are often used for eligibility into clinical trials making it difficult to recruit minoritized adults into Alzheimer’s disease (AD) studies. CognivueClarity®is an FDA-cleared computerized cognitive screening platform using adaptive psychophysics to detect cognitive impairment.ObjectiveTest the ability of CognivueClarityto detect cognitive impairment in a diverse community sample compared with the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS).MethodsThis study enrolled 452 participants across 6 US study sites and completed both CognivueClaritydevice and RBANS. Psychometric properties and exploratory factor analysis of CognivueClaritywere explored and comparisons against RBANS across different age, sex, education, and ethnoracial groups were conducted.ResultsParticipants had a mean age of 47.9±16.1 years (range: 18-85), 63.6% were female, 45.9% had<12 years of education, 31.2% were African American and 9.2% were Hispanic. CognivueClarityhad strong internal consistency, test-retest and minimal practice effects. A 4-factor structure (Memory, Attention, Visuomotor, and Discrimination) had excellent goodness of fit. Normalizing age effects improved performance. Race and education effects were similar to those seen with RBANS. CognivueClarityhad strong correlation with RBANS.ConclusionsOur study supports the use of CognivueClarityas an easy-to-use, brief, and valid cognitive assessment that can be used for identifying individuals with likely cognitive impairment in the clinical setting and those who could be candidates for AD research studies.